Kisunla
Kisunla (donanemab-azbt) treatment for early symptomatic Alzheimer’s Disease, which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
What it treats
Early symptomatic Alzheimer's disease
Prescribed by
Neurologists
How it’s administered
Intravenous (IV) infusion
Frequency
Every 4 weeks
Length of treatment
18 months